Background: Incontinence constitutes a major health problem affecting millions of people worldwide. The present study aims to assess cure rates from treating urinary (UI) or fecal incontinence (FI) and the number of people who may remain dependent on containment strategies.
Methods: Medline, Embase, PsycINFO, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, and PEDro were searched from January 2005 to June 2015. Supplementary searches included conference abstracts and trials registers (2013-2015). Included studies had patients ≥ 18 years with UI or FI, reported treatment cure or success rates, had ≥ 50 patients treated with any intervention recognized in international guideline algorithms, a follow-up ≥ 3 months, and were published from 2005 onwards. Title and abstract screening, full paper screening, data extraction and risk-of-bias assessment were performed independently by two reviewers. Disagreements were resolved through discussion or referral to a third reviewer where necessary. A narrative summary of included studies is presented.
Results: Most evidence was found for UI: Surgical interventions for stress UI showed a median cure rate of 82.3% (interquartile range (IQR), 72-89.5%); people with urgency UI were mostly treated using medications (median cure rate for antimuscarinics = 49%; IQR, 35.6-58%). Pelvic floor muscle training and bulking agents showed lower cure rates for UI. Sacral neuromodulation for FI had a median cure rate of 38.6% (IQR, 35.6-40.6%).
Conclusions: Many individuals were not cured and hence may continue to rely on containment. No studies were found assessing success of containment strategies. There was a lack of data in the disabled and in those with neurological diseases, in the elderly and those with cognitive impairment. Surgical interventions were effective for stress UI. Other interventions for UI and FI showed lower cure rates. Many individuals are likely to be reliant on containment strategies.
Prospero Registration: PROSPERO registration number: CRD42015023763 .
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364653 | PMC |
http://dx.doi.org/10.1186/s12916-017-0828-2 | DOI Listing |
Int J Mol Sci
December 2024
Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, 66421 Homburg, Germany.
Head and neck squamous cell carcinomas (HNSCC) have an overall poor prognosis, especially in locally advanced and metastatic stages. In most cases, multimodal therapeutic approaches are required and show only limited cure rates with a high risk of tumor recurrence. Anti-PD-1 antibody treatment was recently approved for recurrent and metastatic cases but to date, response rates remain lower than 25%.
View Article and Find Full Text PDFJ Clin Med
December 2024
Canterbury Child Development Research Group, School of Health Sciences, University of Canterbury, Christchurch 8140, New Zealand.
Children born with a very low birthweight (VLBW; <1500 g) and/or very preterm (VPT; <32 weeks) are at increased risk of mental health problems, but adult data are inconsistent. We examined the prevalence of a range of mental health disorders in a national cohort of adults born with a VLBW, as well as associations between gestational age and mental health outcomes. All infants born with a VLBW in New Zealand in 1986 were followed prospectively from birth.
View Article and Find Full Text PDFGenes (Basel)
December 2024
Department of Biochemistry & Biotechnology, School of Health Sciences, University of Thessaly, 41335 Larissa, Greece.
Background/objectives: Testicular germ cell tumors (TGCT) are common in young adult men and have high cure rates. Conventional serum tumor markers and imaging are not able to differentiate between histologic subtypes of the disease, which portend different prognoses and require distinct therapeutic strategies. Micro-RNAs (miRNAs) are small non-coding transcripts involved in the post-transcriptional regulation of gene expression, which have emerged as promising biomarkers in a variety of tumors.
View Article and Find Full Text PDFAntibiotics (Basel)
December 2024
Department of Infectious Diseases, St. Luke's International Hospital, Tokyo 104-8560, Japan.
: Tedizolid (TZD), an oxazolidinone, causes fewer adverse events than linezolid (LZD). However, studies on the long-term efficacy and safety of TZD, particularly in patients with hematological malignancies (HMs), remain limited. This study aimed to evaluate the safety of long-term TZD use in Japanese patients, including those with HM.
View Article and Find Full Text PDFAntibiotics (Basel)
December 2024
BioNTech R&D (Austria) GmbH, Helmut-Qualtinger-Gasse 2, 1030 Vienna, Austria.
: The high recurrence rate of bacterial vaginosis (BV) after antibiotic treatment is at least partially attributed to resistant bacteria. The CAPRISA 083 (CAP083) study investigated the influence of metronidazole (MTZ) treatment on the vaginal microbiome in 56 South African women diagnosed with BV. To explore the etiology of recurrent BV in this cohort, we retrospectively analyzed vaginal swabs collected in CAP083 before and after MTZ treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!